Research Topics
| Konstantin ChumakovSummaryAffiliation: Food and Drug Administration Country: USA Publications
| Collaborators
|
Detail Information
Publications
New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitisKonstantin Chumakov
Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20852, USA
Clin Infect Dis 47:1587-92. 2008..Here, we discuss the desired properties of a vaccine and methods to create a new polio vaccine...
MAPREC assay for quantitation of mutants in a recombinant flavivirus vaccine strain using near-infrared fluorescent dyesBella Bidzhieva
Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA
J Virol Methods 175:14-9. 2011..The modified MAPREC assay could be used as an alternative to the radioisotope-based standard protocol for quality control of live viral vaccines...- Microarray hybridization for assessment of the genetic stability of chimeric West Nile/dengue 4 virusMajid Laassri
Laboratory of Method Development, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20852 1448, USA
J Med Virol 83:910-20. 2011..The approach described in this article could be useful for monitoring the molecular consistency and quality control of vaccine strains... - Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccinesAlexander Neverov
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
Proc Natl Acad Sci U S A 107:20063-8. 2010..This approach may represent the ultimate tool for monitoring genetic consistency of live viral vaccines... 
Vaccination against polio should not be stoppedKonstantin Chumakov
Konstantin Chumakov is at the Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852, USA
Nat Rev Microbiol 5:952-8. 2007..It is crucially important that high levels of population immunity are maintained against polio in the foreseeable future...- Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxisZhaochun Chen
National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA
J Virol 85:4354-62. 2011..The MAbs described here could be tested in clinical trials to determine whether they might be useful for treatment of immunocompromised chronic virus excretors and for emergency protection of contacts of a paralytic poliomyelitis case... - Repertoire of antibodies against type 1 poliovirus in human seraGennady Rezapkin
FDA Center for Biologics Evaluation and Research, Rockville, MD 20852, USA
J Virol Methods 169:322-31. 2010..The new method may be useful for analyzing results of clinical trials and to compare immunity induced by different poliovirus vaccines... - Microarray-based assay for the detection of genetic variations of structural genes of West Nile virusAndriyan Grinev
Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Rockville, MD 20852, USA
J Virol Methods 154:27-40. 2008.... - Sequence diversity of Jeryl Lynn strain of mumps virus: quantitative mutant analysis for vaccine quality controlGeorgios Amexis
Center for Biologics Evaluation and Research, FDA Rockville, Maryland 20852, USA
Virology 300:171-9. 2002..Based on the findings presented here, it is proposed that the substrain composition of Jeryl Lynn vaccine can be monitored as a part of its quality control to ensure consistency of the vaccine... - Recovery of strains of the polyomavirus SV40 from rhesus monkey kidney cells dating from the 1950s to the early 1960sKeith Peden
Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
Virology 370:63-76. 2008..These results, and those of others, suggest that a limited number of SV40 strains might exist in rhesus macaques in the United States, and thus determining the origin of the SV40 sequences detected in human tumors might be difficult... - Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R geneMajid Laassri
Center for Biologics Evaluation and Research, US Food and Drug Administration, 1401 Rockville Pike, HFM 470, Rockville, Maryland 20852, USA
J Med Virol 79:791-802. 2007..Potentially, the proposed method could be used as an identity test and could be extended for the entire viral genome and used to monitor consistency of vaccine production... - Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridizationMajid Laassri
Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, HFM-470, Rockville, MD 20852, USA
J Clin Microbiol 43:2886-94. 2005..The amplified full-length viral cDNA can be archived and used to recover live virus for further virological studies... - Detection and discrimination of orthopoxviruses using microarrays of immobilized oligonucleotidesMajid Laassri
Laboratory of Method Development, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, HFM-470, Rockville, MD 20852, USA
J Virol Methods 112:67-78. 2003..The oligonucleotide microarray hybridization technique identified reliably and correctly all samples. This new procedure takes only 3 h, and it can be used for parallel testing of multiple samples... - Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccinesMajid Laassri
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20852, USA
J Infect Dis 193:1344-9. 2006..Polioviruses of Sabin types 2 and 3 reverted more easily than those of type 1. Prior vaccination with IPV did not increase the proportion of revertants after OPV administration... - Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived poliovirusesElena Cherkasova
Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, HFM 470, Rockville, MD 20852, USA
Proc Natl Acad Sci U S A 100:9398-403. 2003..The proposed methods for fine genotyping of heterogeneous viral populations can also have utility for a variety of other applications in studies of genetic changes in viruses, bacteria, and genes of higher organisms... - Changes in mumps virus gene sequence associated with variability in neurovirulent phenotypeSteven A Rubin
DVP Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
J Virol 77:11616-24. 2003..The potential role of these amino acid changes in neurotropism, neurovirulence, and neuroattenuation is discussed... - Effect of different vaccination schedules on excretion of oral poliovirus vaccine strainsMajid Laassri
Center for Biologics Evaluation and Research, Food and Drug Administration, Baltimore, Maryland, USA
J Infect Dis 192:2092-8. 2005..This suggests that IPV-vaccinated communities are partially protected from the spread of poliovirus. Further enhancement of IPV potency may lead to even higher levels of mucosal immunity... - Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV)Gennady Rezapkin
Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, HFM 470, Rockville, MD 20852, USA
Biologicals 33:17-27. 2005..An in-house Reference Reagent was formulated and calibrated against the International Reference for IPV... - Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA methodGennady Rezapkin
Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, HFM 470, Rockville, MD 20852, USA
Biologicals 33:29-39. 2005.... - Medical applications of microarray technologies: a regulatory science perspectiveEmanuel F Petricoin
Division of Therapeutic Products, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland 20892, USA
Nat Genet 32:474-9. 2002.... - Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in miceDiana Kouiavskaia
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20852, USA
Clin Vaccine Immunol 18:1387-90. 2011..A strategy involving coadministration of antiviral V-073 and IPV can be considered for the management of poliovirus incidents...